It was a good week for companies focused on minimally invasive brain surgery. Monteris Medical Corp. received $35 million in a series D equity financing and a $38 million debt facility to support market adoption and clinical research on its Neuroblate system, a laser ablation system that provides a minimally invasive option for brain surgery. Nico Corp. also raised additional funds, with a $12.5 million oversubscribed round for its devices, which do not require cutting through the brain but instead use the natural folds of the brain to reach abnormalities.

Implanet SA reported having raised $2.7 million to ramp up commercial distribution of its spine implants designed for minimally invasive surgery for spine deformities. The exercise took the form of a capital increase in cash with maintenance of shareholder preferential subscription rights launched a month ago.

Cresilon Inc. raised $25 million in a series A-4 financing round led by Paulson Investment Co. The funds will be used to commercialize its plant-based hemostatic gel for human applications and bring it to global veterinary markets. Known as Vetigel in animal medicine, the product is used by veterinarians to instantly stop bleeding in dental and surgical procedures and emergency situations in the U.S., U.K., Europe and Canada.

Ernst & Young’s (EY) annual Pulse of the Industry report offers plenty of reasons for optimism within med tech as the impact of the pandemic recedes, while identifying several key areas that will require continued focus for the sector’s long-term success.

The U.K. is launching a £230 million (US$260 million) project to build a database linking the health records and genetic information of 5 million people, which will be open for discovery research and as a source of clinical trial recruits for academics and companies.